Accumen releases EUA COVID-19 saliva testing kits
October 2020—Accumen announced a partnership with medical equipment manufacturer Spectrum Solutions to provide saliva testing kits for detecting COVID-19.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
OGT’s CytoSure v3 improves reporting rate
October 2020—According to a recent NPJ Genomic Medicine paper (Jezkova J, et al. 2020;5:28), Oxford Gene Technology’s CytoSure Constitutional v3 array design significantly improved reporting rate and proved to be a powerful tool for the detection of small pathogenic intragenic deletions and duplications in developmental disorder research. The paper was led by a consortium of National Health Service genomic medicine centers in the U.K.; it compared the enhanced exon-level gene coverage of the v3 array with a conventional array design.
Bruker introduces MALDI-2 source on TimsTOF Flex
September 2020—Bruker announced an advance in matrix-assisted laser desorption ionization with the launch of its MALDI-2 post-ionization (PI) source, now available as an option on the TimsTOF Flex ESI/MALDI mass spectrometer. The MALDI-2 technology can offer one or two orders of magnitude higher sensitivity for many small molecules and lipids, Bruker said. MALDI-2 increases the applications range of MALDI mass spectrometry and imaging even further. Bruker launched additional TIMS/PASEF-enabled 4D proteomics methods that leverage the large-scale, real-time availability of accurate collision cross sections (CCS) for thousands of measured peptides per 4D nanoLC-CCS-MS/MS run.
Power of Process, LabVine offer online lab program
September 2020—Power of Process, an international learning and development company, and LabVine have partnered to provide an online laboratory performance improvement program, hosted on Labvinelearning.com. The program consists of the Power of Process Champion and Power of Process Master courses followed by a three-month workplace component to embed learning.
Luminex receives EUA for COVID-19 antibody test
September 2020—Luminex Corp. announced that the FDA issued an emergency use authorization for the company’s xMAP SARS-CoV-2 Multi-Antigen IgG Assay. The assay demonstrated specificity of 100 percent in human serum and greater than 99 percent in human plasma, with sensitivity greater than 96 percent for human serum and plasma (>14 days post-symptom onset) in clinical studies.
Microbiologics expands viral capabilities for SARS-CoV-2
September 2020—Microbiologics has expanded its custom virology solutions in its renovated virology services lab to include biosafety level 3 antiviral services. With these new capabilities, the company has launched a menu of cell-based services for SARS-CoV-2 to assist assay developers, evaluate therapeutic solutions and vaccines, and provide inactivated intact virus to researchers and diagnostic companies.
Sofia SARS Antigen FIA receives CE mark
September 2020—The Sofia SARS Antigen Fluorescent Immunoassay received the CE mark for use with the Sofia and Sofia 2 instruments. The CE mark allows Quidel to market and sell the Sofia SARS Antigen FIA in Europe and in countries that accept the CE mark. The test provides results in 15 minutes.
Siemens SARS-CoV-2 test evaluated in PHE study
September 2020—Public Health England evaluated four commercial immunoassay tests used for the detection of SARS-CoV-2 antibodies and available in the United Kingdom.
GenMark launches ePlex RP2 Panel
September 2020—GenMark Diagnostics announced that its ePlex Respiratory Pathogen 2 Panel is available for U.S. commercial distribution and clinical use.
EliTechGroup cytology slide stainer cytocentrifuge
September 2020—EliTechGroup launched its Aerospray Cytology Slide Stainer Cytocentrifuge, which automates the preparation and staining of liquid-based cytology specimens to facilitate the examination of an array of cell differentiations using Papanicolaou staining techniques. The device performs two functions of sample preparation through cytocentrifugation and sample staining. It maximizes cell recovery to the slide through the use of its Cytopro Rotor, eliminates cross-contamination with an application of fresh stain for each slide, and provides programmable regressive and progressive staining capabilities that can be stored in memory.